Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares (NQ:LSE)

PPHC Announces New $105 Million Senior Secured Credit Facility

November 02, 2026

Performance

52-Week Range 36.7% below 52-week high

4.420

3.2052W Low 6.9852W High

1 Week 11.8% below 1-week high

4.141W Low 5.011W High

Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares (LSE) traded between $3.20 and $6.98 over the past 52 weeks and last traded at $4.42, 36.7% below its 52-week high. Over the past week it ranged between $4.14 and $5.01.

Past 12 Months

N/A

-1.6%

-10.3%

-11.1%

+3.5%

-16.0%

1M -$0.07

3M -$0.51

6M -$0.55

YTD +$0.15

1Y -$0.84

LSE was -16.0% over the past year, -11.1% over six months, +3.5% year to date.

12 Months vs Market

LSE

-16.0%

DIA

+12.1%

SPY

+12.1%

QQQ

+10.6%

IWM

+15.0%

Over the past 12 months LSE returned -16.0% versus DIA (Dow) +12.1%, SPY (S&P 500) +12.1%, QQQ (Nasdaq 100) +10.6% and IWM (Russell 2000) +15.0%.

Volume & Liquidity 0.10× 3-mo avg

Today 458 3-mo avg 4.6K

3.3K

3.0K

4.6K

9.8K

YTD

11.7K

10.6K

LSE most recently traded 458 shares against a 3-month average daily volume of 4.6K.

More News

PPHC Announces Acquisition of Reevemark

November 02, 2026

HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan

November 01, 2026

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

October 28, 2026

PPHC to Report Third Quarter 2026 Financial Results and Participate in Upcoming Investor Conference

October 28, 2026

Ahead of a January 2027 Pentagon Sourcing Rule, Tungsten Projects Outside China Move Into Permits and Restarts

October 27, 2026

From Equity Insider

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

October 26, 2026

Avacta Group plc: Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers

October 26, 2026

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

October 26, 2026

HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

October 25, 2026

Avacta Highlights pre|CISION® Platform Data and Ongoing FOCUS-01 Trial Design with FAP-Exd (AVA6103)

October 23, 2026

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

October 20, 2026

Seeing Machines launches Technical Paper demonstrating real-time 3D human understanding for Physical AI

September 30, 2026

From Seeing Machines

Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update

September 30, 2026

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

September 28, 2026

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

September 27, 2026

Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer

September 25, 2026

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

September 23, 2026

The Elmet Group Secures Long-Term Tungsten Offtake Agreement with Tungsten West’s Hemerdon Mine

September 22, 2026

From The Elmet Group

Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial

September 16, 2026

Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee

September 14, 2026

PPHC Increases 2026 Interim Dividend to $0.117 Per Share

September 11, 2026

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

September 03, 2026

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

August 30, 2026